Hemorrhagic Coagulation Disorders and Ischemic Stroke: How to Reconcile Both?

IF 3.2 Q2 CLINICAL NEUROLOGY Neurology International Pub Date : 2023-11-30 DOI:10.3390/neurolint15040093
Pietro Crispino
{"title":"Hemorrhagic Coagulation Disorders and Ischemic Stroke: How to Reconcile Both?","authors":"Pietro Crispino","doi":"10.3390/neurolint15040093","DOIUrl":null,"url":null,"abstract":"<p><p>Coagulation and fibrinolytic system disorders are conditions in which the blood's ability to clot is impaired, resulting in an increased risk of thrombosis or bleeding. Although these disorders are the expression of two opposing tendencies, they can often be associated with or be a consequence of each other, contributing to making the prognosis of acute cerebrovascular events more difficult. It is important to recognize those conditions that are characterized by dual alterations in the coagulation and fibrinolytic systems to reduce the prognostic impact of clinical conditions with difficult treatment and often unfortunate outcomes. Management of these individuals can be challenging, as clinicians must balance the need to prevent bleeding episodes with the potential risk of clot formation. Treatment decisions should be made on an individual basis, considering the specific bleeding disorder, its severity, and the patient's general medical condition. This review aims to deal with all those forms in which coagulation and fibrinolysis represent two sides of the same media in the correct management of patients with acute neurological syndrome. Precision medicine, personalized treatment, advanced anticoagulant strategies, and innovations in bleeding control represent future directions in the management of these complex pathologies in which stroke can be the evolution of two different acute events or be the first manifestation of an occult or unknown underlying pathology.</p>","PeriodicalId":19130,"journal":{"name":"Neurology International","volume":"15 4","pages":"1443-1458"},"PeriodicalIF":3.2000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10745771/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/neurolint15040093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Coagulation and fibrinolytic system disorders are conditions in which the blood's ability to clot is impaired, resulting in an increased risk of thrombosis or bleeding. Although these disorders are the expression of two opposing tendencies, they can often be associated with or be a consequence of each other, contributing to making the prognosis of acute cerebrovascular events more difficult. It is important to recognize those conditions that are characterized by dual alterations in the coagulation and fibrinolytic systems to reduce the prognostic impact of clinical conditions with difficult treatment and often unfortunate outcomes. Management of these individuals can be challenging, as clinicians must balance the need to prevent bleeding episodes with the potential risk of clot formation. Treatment decisions should be made on an individual basis, considering the specific bleeding disorder, its severity, and the patient's general medical condition. This review aims to deal with all those forms in which coagulation and fibrinolysis represent two sides of the same media in the correct management of patients with acute neurological syndrome. Precision medicine, personalized treatment, advanced anticoagulant strategies, and innovations in bleeding control represent future directions in the management of these complex pathologies in which stroke can be the evolution of two different acute events or be the first manifestation of an occult or unknown underlying pathology.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
出血性凝血障碍和缺血性中风:如何兼顾两者?
凝血和纤溶系统疾病是指血液凝固能力受损,导致血栓形成或出血风险增加的疾病。虽然这些疾病是两种对立倾向的表现,但它们往往相互关联或互为因果,导致急性脑血管事件的预后更加困难。重要的是要认识到那些以凝血和纤溶系统双重改变为特征的病症,以减少临床病症对预后的影响,这些病症治疗困难,往往会造成不幸的结果。对这些患者的管理可能具有挑战性,因为临床医生必须在预防出血发作的需要与血栓形成的潜在风险之间取得平衡。治疗决定应根据个体情况做出,并考虑具体的出血性疾病、其严重程度以及患者的一般医疗状况。本综述旨在探讨在正确治疗急性神经综合征患者的过程中,凝血和纤溶是同一介质的两个方面。精准医学、个性化治疗、先进的抗凝策略以及出血控制方面的创新代表了治疗这些复杂病症的未来方向,在这些病症中,中风可能是两种不同急性事件的演变,也可能是隐匿或未知潜在病症的首次表现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Neurology International
Neurology International CLINICAL NEUROLOGY-
CiteScore
3.70
自引率
3.30%
发文量
69
审稿时长
11 weeks
期刊最新文献
Sensitization and Habituation of Hyper-Excitation to Constant Presentation of Pattern-Glare Stimuli. Evolution of Cognitive Disorders in Patients with Mild Cognitive Impairment (MCI) After Ischemic Stroke: Secondary Data Analysis from the Improved Health Care in Neurology and Psychiatry-Longer Life (IHCNP) Study. Macamides as Potential Therapeutic Agents in Neurological Disorders. Slow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYY6 Is More Advantageous in Treating Ongoing Experimental Autoimmune Encephalomyelitis. Mindfulness-Based Interventions and the Hypothalamic-Pituitary-Adrenal Axis: A Systematic Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1